Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Zhejiang Jianfeng Pharmaceutical Co., Ltd. was established on December 31, 1998 and is a subsidiary of Zhejiang Jianfeng Group Co., Ltd. (stock code: 600668).
The company has a registered capital of 0.298 billion yuan and has more than 1000 employees. The company has 5 wholly-owned, holding and shareholding pharmaceutical manufacturing companies, 3 pharmaceutical trading companies, 3 national post-doctoral research workstations, and 2 provincial academician expert workstations. It has 52 international and domestic pharmaceutical invention patents, and its leading product market share ranks among the top 3. The company has been awarded many times as a national key high-tech enterprise, a national intellectual property demonstration enterprise, an innovative demonstration enterprise in Zhejiang Province, a patent demonstration enterprise in Zhejiang Province, a "contract-abiding, credit-honoring" AAA enterprise in Zhejiang Province, and one of the top ten employers in the pharmaceutical industry. With honors, the "Peak" trademark has been recognized as a well-known trademark in China. The company has achieved high-quality development with projects and funds as the link. The company cooperated with German research institutions to establish a Sino-German joint venture Zhejiang Erying Pharmaceutical Co., Ltd., which specializes in the R & D, production and operation of infant drugs; holding Shanghai Beika Pharmaceutical Technology Co., Ltd., specializing in the R & D of pharmaceutical and chemical intermediates and pharmaceutical raw materials, Production and operation to expand the international market of high-end pharmaceutical raw materials and intermediates. The company will adhere to scientific and technological innovation, take technology and products as the carrier, promote the integration of production, teaching and research, constantly improve the company's management level and brand influence, and take the road of international development.
company adheres to the enterprise spirit of "making high-quality medicine", pursues the business philosophy of "science and technology to create health", and insists on developing high-tech, high-value-added chemical raw materials and new chemical preparations. Natural product extraction and Chinese patent medicine preparations are supplemented, and at the same time pay attention to the new drug development ideas of biological agents, and will enter the field of health products in due course. At present, the company to anti-infective drugs, cardiovascular drugs and antidepressants three series of products as the main line. The company will be first-class business philosophy, first-class production management, creating first-class products, casting the public trust of the famous brand, the achievement of human health!
Shanghai Beika Pharmaceutical Technology Co., Ltd.
was established in 2003. It is an innovative company based on chemical science, dedicated to licensed production in the field of medicine and pesticide, and providing customized research and development services for new drugs in major pharmaceutical companies at home and abroad. In 2016 and 2018, it successively completed the wholly-owned acquisitions of Anhui Xinbeika Chemical Co., Ltd. (formerly Changtai Chemical, hereinafter referred to as "Anhui Xinbeika") and Anhui Jianfeng Beika Pharmaceutical Co., Ltd. (formerly Zhongwang Pharmaceutical, hereinafter referred to as "Anhui Jianfeng Beika"), from technology research and development to manufacturing high-tech enterprises integrating research and development, manufacturing and sales in the fields of medicine, pesticides and materials.
At the beginning of its establishment, North Carolina Medicine relied on the anti-tumor research group of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and was committed to the development of various anti-tumor drugs. It has a professional and efficient R & D and technical support team. Institute, East China Normal University, East China University of Science and Technology, Shanghai University of Engineering Science and Technology, Shanghai University of Applied Sciences and Hefei University of Technology, Anqing Normal University, chizhou College and other institutions have carried out R & D and innovation cooperation, as well as talent exchange and training. Over the years, it has always adhered to "technological innovation" as the leader and "quality assurance" as the core. North Carolina Pharmaceuticals has continuously consolidated its own foundation in the industry, team, manufacturing and service ends, and has accumulated rich industrial experience. In terms of market development and industrial development, North Carolina adopts various channels such as technical services, strategic cooperation, channel development, and product management to actively explore its own development, growth, upgrading and transformation in the process of creating value for customers and solving pain points. In 2017, Shanghai North Carolina Academician Expert Workstation was established. In September 2018, a small molecule targeted drug research institute was set up in Anhui. Shanghai North Carolina completed the pilot project of cultivating small giants and joined Songjiang G60 science and technology enterprises in 2019.
North Carolina Pharmaceuticals and its two wholly-owned subsidiaries currently have a total of nearly 480 employees. In the 4 7 environment, North Carolina Pharmaceuticals will "lay out high-end generic drugs, dig deep into green production routes, and improve product quality" as its long-term goal. Member enterprises Anhui Xinbeika and Anhui Jianfeng Beika have equipment and production lines that have various hazardous chemicals use qualifications and realize various hazardous reactions, and cooperate with domestic pharmaceutical preparation enterprises to jointly build a green pharmaceutical platform and promote more CDMO/CMO development. On this basis, North Carolina Pharmaceuticals has increased its investment in technology and safety, cooperated with more advanced safety, environmental protection and equipment platforms, and marked "green", "safe", "efficient" and "personnel-friendly" from the initial design of the process route. Brand, to create a high-standard high-starting-point API and intermediate production platform.
At the same time, North Carolina Pharmaceuticals actively carries out the research, production and various cooperation of drugs and their advanced intermediates under the MAH/GMP standard, and strives to build a standardized platform for chemical pharmaceuticals to provide a powerful boost to the pharmaceutical industry.